Document Detail

Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation.
MedLine Citation:
PMID:  16598396     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Relatively few reports on the clinical impact of atrial fibrillation (AF) in hypertrophic obstructive cardiomyopathy (HOCM) are available. The aims of our study are to report the effect of transcoronary ablation of septal hypertrophy (TASH) on clinical outcome in HOCM associated with AF and to evaluate the influence of AF on symptoms and quality of life in HOCM. PATIENT AND METHODS: In 80 consecutive patients (38 f, mean age 56 +/- 17 years) with severely symptomatic HOCM referred for interventional treatment, we analyzed the prevalence of AF based on 240 Holter ECG recordings and patients' history, retrospectively. Symptoms, quality of life, number of hospital admissions and hemodynamic performance were obtained in all patients before and after TASH. Mortality was additionally investigated by letter and telephone contact. RESULTS: The overall prevalence of AF was 29%. Paroxysmal AF was detected in 17 pts (21.3%), persistent AF in 5 pts (6.3%). Only 1 pt (1.3%) suffered from permanent AF. Symptoms due to AF were present in 52.6% of the AF patients. Quality of life score was markedly improved after TASH (15.9 +/- 3.8 vs. 20.7 +/- 3.8, p < 0.001) with no difference between sinus rhythm and atrial fibrillation. However, hospital admissions were more frequent in the AF group (0.85 +/- 1.84 vs. 0.28 +/- 0.81, p = 0.03) in 32 +/- 13 months. AF patients suffered more often from syncope before TASH (30 +/- 70% vs. 10 +/- 30%, p = 0.008). Two patients with sinus rhythm at baseline died after 32 +/- 13 months from cardiovascular cause. CONCLUSIONS: Atrial fibrillation is the major cardiac arrhythmia in severe HOCM. The majority of AF patients demonstrate AF specific symptoms. The paroxysmal type of atrial fibrillation dominates by far. Both patients with and without atrial fibrillation showed similar quality of life with marked improvement after TASH.
L Obergassel; T Lawrenz; F H Gietzen; F Lieder; C Leuner; H Kuhn; C Stellbrink
Related Documents :
17332026 - Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation ...
15234426 - Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a ...
16053206 - Medulloblastoma and birth date: evaluation of 3 u.s. datasets.
21333556 - Spontaneous cerebral embolisation in asymptomatic and recently symptomatic patients wit...
20179696 - The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: res...
6201996 - Correlation between serum concentrations of three specific exocrine pancreatic proteins...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2006-03-21
Journal Detail:
Title:  Clinical research in cardiology : official journal of the German Cardiac Society     Volume:  95     ISSN:  1861-0684     ISO Abbreviation:  -     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-08     Completed Date:  2007-05-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101264123     Medline TA:  Clin Res Cardiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  254-60     Citation Subset:  IM    
Department of Cardiology and Internal Intensive Medicine, The Bielefeld Community Hospital, Academic Teaching Hospital of the University of Muenster, Bielefeld, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atrial Fibrillation / diagnosis,  epidemiology*,  prevention & control*
Cardiomyopathy, Hypertrophic / diagnosis,  epidemiology*,  therapy*
Ethanol / therapeutic use*
Germany / epidemiology
Middle Aged
Quality of Life*
Risk Assessment / methods
Risk Factors
Treatment Outcome
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) i...
Next Document:  Transradial unprotected left main coronary stenting supported by percutaneous Impella Recover LP 2.5...